A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With
A phase 1/2 trial of Camizestrant, Ribociclib, Palbociclib in ovarian cancer, run by AstraZeneca, now recruiting.
Overview
A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT06188520 by AstraZeneca, with 564 participants planned, started 2023-12-05 and due to reach its primary completion in 2027-08-04. Interventions recorded: AZD8421, Camizestrant, Ribociclib, Palbociclib, Abemaciclib. Conditions listed: ER+ HER2- Advanced Breast Cancer, High-grade Serous Ovarian Cancer (HGSOC). No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialSaruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
Shares Camizestrant, Ribociclib, Abemaciclib, Palbociclib.
- TrialCapivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)
Shares Ribociclib, Abemaciclib, Palbociclib, AstraZeneca.
- TrialA Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease
Shares Camizestrant, Palbociclib, AstraZeneca.
- TrialA Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer
Shares Camizestrant, Ribociclib, AstraZeneca.
- TrialStudy of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
Shares Ribociclib, Abemaciclib, Palbociclib.
- TrialStudy of AVZO-021 in Patients With Advanced Solid Tumors
Shares Ribociclib, Abemaciclib, Palbociclib, Ovarian cancer.
- TrialA Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC
Shares Ribociclib, Abemaciclib, Palbociclib.
- TrialA Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
Shares Ribociclib, Abemaciclib, Palbociclib.